Evaluation of N-Hydroxy-, N-Metoxy-, and N-Acetoxybenzoyl-Substituted Derivatives of Thymine and Uracil as New Substances for Prevention and Treatment of Long-Term Complications of Diabetes Mellitus


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

New uracil and thymine derivatives, N1-,N3- and N1,N3-(RO-benzoyl)-(1H,3H)-pyrimidine- 2,4-diones, were synthesized (RO- is hydroxy, acetoxy- or methoxy-group). The compounds were studied in a complex of in vitro tests for the ability to inhibit the development of long-term complications of diabetes. Their ability to cleave cross-links of proteins has been evaluated. The most significant ways of pharmacological correction of thrombosis, angio-, nephro-, encephalo-, and cardiopathy, antiglycation, chelating, and antiplatelet activities, have been established. The most active compound in terms of antiplatelet action, N1- hydroxybenzoyluracil, exceeded acetylsalicylic acid by ~44%. In terms of their ability to chelate copper (II) cations, all compounds (with the exception of 1,3-bis(3-hydroxybenzoyl)-(1H,3H)-pyrimidine-2,4-dione that was not not studied in this test) showed the activity, whose IC50 fell in the range between that for pioglitazone (44.1 μM) and pyridoxamine (136.7 μM) comparison drugs. The best antiglycation effect at the 1 mM concentration was observed for N1,N3-bismethoxy- and N1,N3-bisacetoxybenzoyl derivatives of thymine. The maximum activity to cleave cross-links of proteins (C = 1 mM), comparable to that of alagebrium, was established for 1,3-bis(4-methoxybenzoyl)uracil, for which also high rates of other estimated activities were noted. Thus, the N1-,N3- and N1,N3-(RO-benzoyl) derivatives of uracil and thymine are promising basiсs for creating drugs that suppress the development of long-term complications of diabetes.

Об авторах

A. Spasov

Volgograd State Medical University; Volgograd Medical Scientific Center; Scientific Institute of Pharmacology of VSMU

Email: litvinov.volggmu@mail.ru
Россия, Volgograd, 400131; Volgograd, 400081; Volgograd, 400001

A. Brel

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
Россия, Volgograd, 400131

R. Litvinov

Volgograd State Medical University; Scientific Institute of Pharmacology of VSMU

Автор, ответственный за переписку.
Email: litvinov.volggmu@mail.ru
Россия, Volgograd, 400131; Volgograd, 400001

S. Lisina

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
Россия, Volgograd, 400131

A. Kucheryavenko

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
Россия, Volgograd, 400131

Yu. Budaeva

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
Россия, Volgograd, 400131

O. Salaznikova

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
Россия, Volgograd, 400131

A. Rashchenko

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
Россия, Volgograd, 400131

D. Shamshina

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
Россия, Volgograd, 400131

V. Batrakov

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
Россия, Volgograd, 400131

A. Ivanov

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
Россия, Volgograd, 400131

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML

© Pleiades Publishing, Ltd., 2018

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).